National Cancer Screening and Early Diagnosis Guidelines

Objectives

Kenya’s 2024 National Guidelines for Cancer Screening and Early Diagnosis provide an evidence-based framework to reduce preventable cancer morbidity and mortality through prevention, risk-based screening, prompt diagnosis, referral, treatment and follow-up across public, faith-based and private services.[1][2][3]The guidelines support implementation of the National Cancer Control Strategy 2023–2027 and standardise early detection programmes in accordance with local epidemiology, available resources and international cancer-control initiatives.[1][4]

• Strengthen early diagnosis by improving cancer awareness, health-seeking behaviour, access to care, diagnostic capacity, referral mechanisms and timely treatment for symptomatic patients.[4][5]
• Prioritise population-based screening for cervical, breast and colorectal cancers, while providing targeted or risk-based screening for prostate, oral cancer and retinoblastoma.[6][7]
• Promote prevention through human papillomavirus vaccination, risk-factor reduction, tobacco and alcohol control, and education on cancer symptoms and risk.[8][9][10]
• Link screening to confirmatory diagnosis, treatment of precancerous lesions, patient navigation, follow-up and survivorship or palliative care, rather than treating screening as a stand-alone service.[4][11][12]
• Advance cervical cancer elimination by aiming to screen 70% of women with a high-performance human papillomavirus test and treat 90% of women with precancer or confirmed cancer by 2030.[13]
• Improve childhood cancer outcomes through early recognition, high clinical suspicion, direct referral of highly suspected cases to comprehensive cancer centres and support for the Global Initiative for Childhood Cancer survival target of at least 60% by 2030.[14][15]

Implementation

The guidelines use a coordinated, tiered delivery model spanning community, primary, secondary and tertiary care. It combines awareness creation, risk assessment, screening, diagnosis, referral, treatment, follow-up, quality assurance and data use, with services matched to facility capacity and supported by multidisciplinary teams.[4][16][12]Implementation is intended to involve the Ministry of Health, county governments, healthcare providers, professional bodies, academic institutions, civil society, development partners, facilities, communities and patients.[1][6][3]

• Deliver cervical screening primarily through human papillomavirus testing, with visual inspection with acetic acid or cytology where testing is unavailable or loss to follow-up is likely; use screen-triage-and-treat approaches and single-visit care where feasible.[13][17]Implement self-collection in facility and community settings where appropriate, strengthen linkage from positive results to treatment, and refer suspected cancer immediately for specialist diagnosis and treatment.[17][13]
• Apply risk-stratified breast screening through breast awareness, clinical breast examination, mammography for average-risk women and genetic counselling or enhanced imaging for eligible high-risk women.[18][19]Provide community mobilisation and clinical examination at lower levels of care, with imaging, biopsy, surgery and treatment available at higher-level facilities.[16]
• Implement colorectal screening through phased use of guaiac-based faecal occult blood testing and progressive transition to faecal immunochemical testing as infrastructure improves, with colonoscopy for positive stool tests and higher-risk groups.[20]Maintain colonoscopy capacity at Level 4 to Level 6 facilities, map referral-capable hospitals and standardise referral, biopsy, communication, appointment and follow-up processes.[21]
• Provide individualised prostate-specific antigen testing through shared decision-making rather than mass screening, with testing available from Level 3 facilities and referral of elevated results to urology services, preferably at Level 4 or above.[22][23]
• Integrate oral cancer screening into primary care through visual examination, risk assessment, cessation counselling and referral, supported by trained community health workers, nurses, dental personnel, clinicians and specialist multidisciplinary teams.[24][9][10]
• Establish risk-based retinoblastoma pathways through red-reflex examination, urgent assessment of white pupil or strabismus, family-history assessment, genetic counselling and testing where possible, ophthalmology referral and age-specific surveillance for children at inherited risk.[25][26]
• Strengthen early diagnosis for childhood, oesophageal and other symptomatic cancers through public and provider awareness, red-flag symptom recognition, diagnostic capacity, patient navigation, direct referral pathways and integrated care.[15][27][28]
• Use information systems, line lists, patient navigators, medical records, mobile communication and longitudinal tracking to reduce loss to follow-up and document diagnosis, staging, treatment plans and follow-up status.[12][29]
• Monitor cervical services through monthly performance measures, target coverage, positivity, treatment rates, county and facility screening rates, data use and quarterly scorecards.[30]Monitor colonoscopy quality through caecal intubation rate, adenoma detection rate and withdrawal time, with thresholds of at least 95%, 25% and six minutes respectively.[31][20]Monitor oral cancer programmes through workforce, coverage, referral, facility-capacity, early-stage diagnosis, incidence and five-year survival indicators.[32]
• Ensure programme readiness by maintaining trained personnel, quality control, quality assurance, reliable supply chains, equipment, laboratory and specimen-management systems, referral networks and coordinated leadership.[4][33]The guidelines do not specify a consolidated national budget, financing allocation or quantified funding gap.[2][4]

Monitoring & Evaluation

The guideline combines programme monitoring, service quality assurance, patient tracking and cancer-specific follow-up, but does not provide one consolidated national indicator framework, universal reporting timetable or named accountability structure for all cancer types.[2][4]

• Monitor cervical cancer elimination through monthly screening performance, coverage of the screening target, test positivity, treatment of precancer, county and facility screening rates, and facility-level data use.[30]Review scorecards quarterly, including target achievement and positivity among first-time screened women aged 25–49 years.[30]
• Track progress towards the World Health Organization 2030 cervical cancer targets of screening 70% of women with a high-performance human papillomavirus test and treating 90% of women with precancer or confirmed cancer.[13]Kenya’s reported screening coverage among women aged 25–49 years rose from 5% in 2018 to 30.3% in 2024, while 33% of women with a positive screening test received treatment in 2024.[13]
• Strengthen health information systems to link positive cervical screening results to treatment, identify clients lost to follow-up, document visual inspection with acetic acid findings, and maintain quality control and quality assurance.[13][34]
• Apply defined clinical follow-up schedules, including repeat human papillomavirus testing after cervical precancer treatment and risk-based surveillance for women living with HIV, women with high-grade lesions and post-hysterectomy patients where clinically indicated.[34][35]
• Measure colorectal colonoscopy quality through caecal intubation rate, adenoma detection rate and withdrawal time.[31]Achieve a withdrawal inspection time of at least six minutes, caecal intubation in at least 95% of screening examinations, and an adenoma detection rate of at least 25%.[20]
• Assess colorectal referral-system performance through referral rates, waiting times and patient outcomes, and use feedback and performance data to update referral arrangements.[21]
• Monitor oral cancer services through numbers of trained health workers and people screened, client characteristics and risk factors, referral volumes, facilities able to screen, use of adjunctive tests, early-stage diagnosis, incidence per 100,000 and five-year survival.[32]Include oral cancer indicators in national screening tools and strengthen National Cancer Registries for reporting and surveillance.[11][32]
• Establish prostate cancer data-collection and monitoring systems to assess implementation progress and outcomes, undertake regular evaluation, and adjust guidance, education materials or logistics in response to evidence.[36]
• Use medical records, patient navigators, scheduled contacts, mobile messaging, line-lists and longitudinal tracking to record diagnostic and staging information, management plans and follow-up status within early-diagnosis referral pathways.[12][29]
• Undertake oesophageal cancer monitoring through health-record data, focus groups, routine reporting, site visits, staged evaluations and feedback mechanisms; support registry development to track incidence and outcomes.[27]
• Maintain disease-specific surveillance schedules for retinoblastoma, including ophthalmologist-led examinations under anaesthesia for children with an RB1 mutation and age-based examinations where genetic testing is unavailable.[26]

Costing & Financing

The guideline identifies major equipment, workforce, diagnostic and treatment requirements, and recognises cost-effectiveness considerations, but does not provide a Kenya-specific programme budget, quantified funding gap, expenditure plan or resource-mobilisation target.[2][4]

• Secure sufficient funds, equipment and trained personnel before implementing screening programmes, and assess whether screening tests, diagnostic capacity, treatment, follow-up and available resources justify service delivery.[4]
• Consider costs and benefits, equipment, supplies, distributor arrangements, quality control, training and supply-chain requirements when selecting human papillomavirus tests.[30]Provide laboratory information systems, reagents, specimen-collection systems and treatment equipment for cervical screening, diagnosis and precancer treatment.[33]
• Recognise that routine human papillomavirus and Pap smear co-testing is not cost-effective compared with high-risk human papillomavirus testing alone.[37][17]Self-collection may reduce health-system costs and burden, while visual inspection with acetic acid is inexpensive and does not require laboratory services.[17][34]
• Prioritise affordable colorectal screening approaches where appropriate: guaiac-based faecal occult blood testing and faecal immunochemical testing are recognised as cost-effective, while stool DNA testing and colonoscopy have higher costs.[38][39]Annual faecal immunochemical testing may be cost-effective or cost-saving relative to colonoscopy every 10 years.[39]
• Plan for resource constraints in cervical precancer treatment: thermal ablation is described as low cost but requires electricity, while cryotherapy may be limited by refrigerant gas availability and loop electrosurgical excision procedures require electricity, local anaesthesia, colposcopy and skilled personnel.[40]
• Fund oral and nasopharyngeal cancer screening and diagnostics, including diagnostic equipment, consumables and specialist-centre reagents, although no amounts or funding sources are specified.[11]
• Address direct and indirect out-of-pocket costs, geographic barriers and logistical barriers by increasing treatment availability and leveraging the chronic diseases fund, universal health coverage and the Social Health Insurance Fund.[29]
• Recognise that global direct and indirect cancer prevention and treatment costs are projected to exceed 25.2 trillion dollars between 2020 and 2050.[2]This global estimate is not applied as a Kenyan budget assumption.[7]